DR DOUG QUARRY, MBBS, MSc (Community Health)
US-based biotech company Moderna Inc’s experimental COVID-19 vaccine is one of eight currently being tested on humans.
In the trial, 45 volunteers were divided into three groups. Each received a different dose of the vaccine, an initial dose and a booster one month later.
Preliminary data (not published) shows that all 45 volunteers developed protective antibodies. Eight participants received low and medium doses of the vaccine. All those tested developed antibodies that kill the virus.
The next phase of testing involves 600 volunteers, half older than 55.
Development of the vaccine is a collaboration between Moderna, Inc. and the National Institute of Allergy and Infectious Diseases, of which Anthony Fauci MD is a Director.
